Biopharma | June 05, 2026
Aurobindo Pharma launches TheraNym, India’s largest biologics CMO
MSD joins as anchor customer as Aurobindo strengthens its position in the fast-growing global biologics manufacturing market
MSD joins as anchor customer as Aurobindo strengthens its position in the fast-growing global biologics manufacturing market
The state has received Rs. 84,000 crore investments in the sector over two years, positioning Hyderabad among the world’s leading life sciences clusters
Hyderabad based 400-bed facility brings AI-driven care, advanced imaging, and integrated clinical systems under one roof
Backed by a multi-hundred-million-dollar investment, the expansion underscores Sanofi’s long-term commitment to India’s thriving life sciences ecosystem
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
Investment to expand manufacturing and global medicine supply capacity
The expansion will bring together talent in AI, data science, and engineering to build the digital foundation needed to accelerate drug discovery and delivery
Amgen India investment totals $200 million through 2025
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
